No Picture
News

Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist

CAMBRIDGE, Mass., Sept. 30, 2026 /PRNewswire/ — As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual sales of $36.507 billion in 2025, has… … […]

News

Cytrellis Announces Partnership for Commercialization of ellacorĀ® Micro-CoringĀ® Technology in South Korea

Entry Into Booming South Korean Aesthetic Market Is Key Strategic Growth Milestone WOBURN, Mass., Sept. 29, 2026 /PRNewswire/ — Cytrellis Biosystems, Inc. a medical aesthetics company bridging the gap in skin health and restoration, today announced that it has entered into an agreement… … […]

News

MassBio in Banker & Tradesman: Why Real Estate Has to Be Part of Biotech’s Comeback

In her annual commentary for Banker & Tradesman’s life sciences issue, MassBio CEO & President Kendalle Burlin O’Connell calls on the real estate community to help Massachusetts keep the next generation of biotech companies here. The leases signed this year were set in motion by seed rounds raised three and… … […]

No Picture
News

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

WATERTOWN, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc.Ā (NASDAQ: TECX) (ā€œTectonicā€ or the ā€œCompanyā€), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced favorable… … […]

No Picture
News

Aldeyra Therapeutics to Host Regulatory Update Webcast

CONCORD, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an… … […]